Inclusion Criteria:

- Documented CD19+ CLL or SLL

- Successful test expansion of T-cells (as described in Section 6.1)

- At least 2 prior chemotherapy regimens. At least one fludarabine or other nucleoside
analog containing regimen. Chemotherapy in combination with monoclonal antibody
(Rituxan) will be considered one prior regimen, but single agent Rituxan will not be
considered one prior regimen. Single agent ofatumumbab will be counted as a regimen.

- Less than 2 years between last therapy and progression (e.g. most recent progression
free interval 2 years)

- Subject has no available or declines curative treatment options such as allogeneic
SCT and has limited prognosis (2 years survival) with currently available therapies

- Expected survival 12 weeks

- Performance status (ECOG) 0 or 1

- Age greater than or equal to 18 years

- Adequate organ system function including:

1. Creatinine 1.6 mg/dl

2. ALT/AST 3x upper limit of normal

3. Direct Bilirubin 2.0 mg/dl

- Any relapse after prior autologous SCT will make patient eligible regardless of other
prior therapy

- Patients with relapsed disease after prior allogeneic SCT (myeloablative or
nonmyeloablative) will be eligible if they meet all other inclusion criteria and:

1. experienced graft rejection (no evidence of donor cells by STR analysis on 2
occasions separated by at least 1 month)

2. Have no active GVHD and require no immunosuppression

3. Are more than 6 months from transplant

- No contraindications for leukapheresis

- Gives voluntary informed consent

Exclusion Criteria:

- Pregnant or lactating women. The safety of this therapy on unborn children is not
known. Female study participants of reproductive potential must have a negative serum
or urine pregnancy test performed within 48 hours before infusion.

- Uncontrolled active infection

- Active hepatitis B or hepatitis C infection

- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
exclusionary.

- Any uncontrolled active medical disorder that would preclude participation as
outlined

- HIV infection

- Patients with active CNS involvement with malignancy. Patients with prior CNS disease
that has been effectively treated will be eligible providing treatment was 4 weeks
before enrollment.